All In Biotech

Drug Trial Radar · NCT07458347

A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

A First-in-human Phase 1 Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KST-6051 in Patients With Advanced or Metastatic Solid Tumors With a KRAS Mutation

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

545

Planned (sponsor's estimate)

Start

Apr 21, 2026

Primary completion

Apr 2028

Study completion Apr 2029

Sponsor

Lead sponsor
Kestrel Therapeutics, Inc.Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of the trial is to assess whether the trial drug, KST-6051, is safe and tolerable when administered orally, alone or in combination with other anticancer agents, to adults with advanced or metastatic solid tumors with certain KRAS mutations.

Conditions

  • KRAS-mutant Non-small Cell Lung Cancer (NSCLC)
  • KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)
  • KRAS-mutant Colorectal Cancer (CRC)
  • Other KRAS-mutant Solid Tumors

Interventions

  • KST-6051Drug

    KST-6051 will be administered orally as a tablet.

  • Gemcitabine/nab-paclitaxelDrug

    Gemcitabine/nab-paclitaxel will be administered intravenously (IV).

  • CetuximabDrug

    Cetuximab will be administered IV.

  • PembrolizumabDrug

    Pembrolizumab will be administered IV.

  • mFOLFOX6Drug

    mFOLFOX6 will be administered IV.

  • FOLFIRIDrug

    FOLFIRI will be administered IV.

  • PemetrexedDrug

    Pemetrexed will be administered IV.

  • CarboplatinDrug

    Carboplatin will be administered IV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation Cohorts: Number of Participants With Dose-limiting Toxicities (DLTs) at the end of Cycle 1 (Each Cycle is 21 Days)Time frame: Up to Day 21 of Treatment Cycle 1
  2. Dose Escalation Cohorts: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 2 years
  3. Dose Escalation Cohorts: Number of Participants With Treatment-related Adverse Events (TRAEs)Time frame: Up to approximately 2 years
  4. Dose Expansion Cohorts: Confirmed Objective Response Rate (ORR)Time frame: Up to approximately 2 years

Locations

9 sites in 1 country. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Florida Cancer Specialists

    Sarasota, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Mass General Brigham Cancer Institute at Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Sidney Kimmel Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • NEXT Oncology

    San Antonio, Texas · Recruiting

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah · Recruiting

  • NEXT Virginia

    Fairfax, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.